Literature DB >> 12610153

Infectivity of a human respiratory syncytial virus lacking the SH, G, and F proteins is efficiently mediated by the vesicular stomatitis virus G protein.

A G P Oomens1, A G Megaw, G W Wertz.   

Abstract

To examine the requirements of the human respiratory syncytial virus (HRSV) SH (small hydrophobic), G (attachment), and F (fusion) proteins for virus infectivity and morphology, we used the prototype A2 strain of HRSV to generate a series of cDNAs from which (i) the SH open reading frame (ORF), (ii) the SH and G ORFs, or (iii) the SH, G, and F ORFs were deleted. Each deleted ORF was replaced as follows: the SH ORF was replaced with that of green fluorescent protein; the G ORF was replaced with that of G(vsv), a chimeric glycoprotein consisting of the vesicular stomatitis Indiana virus (VSIV) G protein ecto- and transmembrane domains coupled to the HRSV F cytoplasmic tail; and the F ORF was replaced with that of marker protein beta-glucuronidase. The number of genes and the intergenic junctions in the constructs were kept as found in A2 virus in order to maintain authentic levels of transcription. Infectious viruses were recovered from all three engineered cDNAs and designated RSdeltash, RSdeltash,g/G(vsv), and RSdeltash,g,f/G(vsv), respectively. Low-pH-induced syncytium formation was observed in cells infected with viruses RSdeltaSH,G/G(vsv) and RSdeltaSH,G,F/G(vsv), indicating that G(vsv) was expressed and functional. Neutralization of infectivity by anti-VSIV G antibodies and inhibition of entry by ammonium chloride showed that RSdeltaSH,G,F/G(vsv) infectivity was mediated by G(vsv) and that an acidification step was required for entry into the host cell, similar to VSIV virions. All three engineered viruses displayed growth kinetics and virus yields similar to a wild-type A2 virus, both in Vero and HEp-2 cells. Abundant virus-induced filaments were observed at the surface of cells infected with each of the three engineered viruses or with virus A2, indicating that neither the SH and G proteins nor the F protein ecto- and transmembrane domains were required for the formation of these structures. This is the first report of the recovery of an infectious HRSV lacking a fusion protein of the Paramyxoviridae family and of manipulation of the HRSV entry pathway via incorporation of a nonparamyxoviral transmembrane glycoprotein.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610153      PMCID: PMC149529          DOI: 10.1128/jvi.77.6.3785-3798.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

1.  Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus.

Authors:  S Levine; R Klaiber-Franco; P R Paradiso
Journal:  J Gen Virol       Date:  1987-09       Impact factor: 3.891

2.  The 1A protein gene of human respiratory syncytial virus: nucleotide sequence of the mRNA and a related polycistronic transcript.

Authors:  P L Collins; G W Wertz
Journal:  Virology       Date:  1985-03       Impact factor: 3.616

3.  A cell line expressing vesicular stomatitis virus glycoprotein fuses at low pH.

Authors:  R Z Florkiewicz; J K Rose
Journal:  Science       Date:  1984-08-17       Impact factor: 47.728

4.  Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein.

Authors:  E E Walsh; J Hruska
Journal:  J Virol       Date:  1983-07       Impact factor: 5.103

5.  Identification of a tenth mRNA of respiratory syncytial virus and assignment of polypeptides to the 10 viral genes.

Authors:  P L Collins; Y T Huang; G W Wertz
Journal:  J Virol       Date:  1984-02       Impact factor: 5.103

6.  Characterization of the 10 proteins of human respiratory syncytial virus: identification of a fourth envelope-associated protein.

Authors:  Y T Huang; P L Collins; G W Wertz
Journal:  Virus Res       Date:  1985-03       Impact factor: 3.303

7.  Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.

Authors:  E J Stott; G Taylor; L A Ball; K Anderson; K K Young; A M King; G W Wertz
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

8.  Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice.

Authors:  R A Tripp; D Moore; L Jones; W Sullender; J Winter; L J Anderson
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

9.  Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein.

Authors:  G W Wertz; P L Collins; Y Huang; C Gruber; S Levine; L A Ball
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

10.  Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice.

Authors:  G W Wertz; E J Stott; K K Young; K Anderson; L A Ball
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

View more
  19 in total

1.  The human respiratory syncytial virus matrix protein is required for maturation of viral filaments.

Authors:  Ruchira Mitra; Pradyumna Baviskar; Rebecca R Duncan-Decocq; Darshna Patel; Antonius G P Oomens
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

2.  Novel influenza virus NS1 antagonists block replication and restore innate immune function.

Authors:  Dipanwita Basu; Marcin P Walkiewicz; Matthew Frieman; Ralph S Baric; David T Auble; Daniel A Engel
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

3.  The respiratory syncytial virus fusion protein targets to the perimeter of inclusion bodies and facilitates filament formation by a cytoplasmic tail-dependent mechanism.

Authors:  Pradyumna S Baviskar; Anne L Hotard; Martin L Moore; Antonius G P Oomens
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

4.  Human respiratory syncytial virus glycoproteins are not required for apical targeting and release from polarized epithelial cells.

Authors:  Melissa Batonick; Antonius G P Oomens; Gail W Wertz
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

5.  Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.

Authors:  Bo Liang; Joan O Ngwuta; Richard Herbert; Joanna Swerczek; David W Dorward; Emerito Amaro-Carambot; Natalie Mackow; Barbora Kabatova; Matthias Lingemann; Sonja Surman; Lijuan Yang; Man Chen; Syed M Moin; Azad Kumar; Jason S McLellan; Peter D Kwong; Barney S Graham; Anne Schaap-Nutt; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

6.  Biological differences between vesicular stomatitis virus Indiana and New Jersey serotype glycoproteins: identification of amino acid residues modulating pH-dependent infectivity.

Authors:  Isidoro Martinez; Gail W Wertz
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  RhoA signaling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphology.

Authors:  Tara L Gower; Manoj K Pastey; Mark E Peeples; Peter L Collins; Lewis H McCurdy; Timothy K Hart; Alex Guth; Teresa R Johnson; Barney S Graham
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

8.  Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.

Authors:  Susan E Witko; J Erik Johnson; Narender K Kalyan; Barbara K Felber; George N Pavlakis; Maninder K Sidhu; R Michael Hendry; Stephen A Udem; Christopher L Parks
Journal:  J Virol Methods       Date:  2009-11-24       Impact factor: 2.014

9.  The baculovirus GP64 protein mediates highly stable infectivity of a human respiratory syncytial virus lacking its homologous transmembrane glycoproteins.

Authors:  A G P Oomens; Gail W Wertz
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  The Respiratory Syncytial Virus Phosphoprotein, Matrix Protein, and Fusion Protein Carboxy-Terminal Domain Drive Efficient Filamentous Virus-Like Particle Formation.

Authors:  Chetan D Meshram; Pradyumna S Baviskar; Cherie M Ognibene; Antonius G P Oomens
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.